Form 4: Amgen Director Greg C. Garland Reports Acquisition of Common Stock

Director Greg C. Garland reports acquiring 719 shares of Amgen common stock on May 31, 2024, through vested Restricted Stock Units (RSUs).

Summary

• On May 31, 2024, Greg C. Garland, a director of Amgen Inc., acquired 719 shares of common stock.
• The acquisition was a result of vested Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Director Incentive Program.
• The RSUs vested immediately and are payable in shares of Amgen's common stock on a one-to-one basis.
• Following the transaction, Garland directly owns 12,374 shares of Amgen common stock.
• Vested RSUs can be deferred by the director, with payment occurring according to the elected deferral schedule.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by a director, which doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but it mentions the possibility of deferring vested RSUs, which could impact future stock transactions.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their holdings in the company's stock.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects insider activity, which is generally monitored for insights into management's confidence in the company.

Key Dates